$10 Million In, $8 Billion Out: Pricing Risk Across the Gedatolisib Lifecycle

On July 14, 2026, the FDA approved gedatolisib (Revtorpyk, Celcuity) for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation, in combination with fulvestrant with or without palbociclib [1]. The approval came three days ahead of the PDUFA goal date and landed the first targeted therapy for a population representing roughly 60% of second-line HR+/HER2- metastatic breast cancer patients [2].

Five years earlier, Celcuity acquired worldwide rights to this molecule from Pfizer for $5 million in cash and $5 million in stock upfront [3].

The gap between what Pfizer accepted and what the asset became is not an anomaly. It is a working demonstration of how risk-adjusted valuation frameworks, applied at different stages of a drug's lifecycle, produce dramatically different numbers for the same molecule. This article walks through those frameworks using gedatolisib as a live case. We trace the asset's risk-adjusted net present value (rNPV) at four inflection points, apply a real options lens to what Pfizer forfeited, and examine what the competitive landscape and clinical data contributed to each valuation step.

The objective is practical: to show how the valuation tools we discuss on this blog behave when applied to a real, recently approved drug, with real deal terms and real clinical endpoints.

A $10 million exit from a troubled class

In April 2021, Celcuity signed a worldwide exclusive license with Pfizer for gedatolisib (then PF-05212384). The deal terms were sparse by biotech standards [3]:

Gedatolisib originated at Wyeth. Pfizer inherited it through the 2009 Wyeth acquisition and continued early clinical development [3]. By 2021, the PI3K inhibitor class was in disrepute. Pfizer had terminated another PI3K/mTOR drug over tolerability concerns, and Eli Lilly had dropped a similar program after reviewing clinical data [4]. The prevailing sentiment was that PI3K inhibitors were commercially unviable due to metabolic toxicity and narrow therapeutic windows.

Pfizer's decision to license rather than advance gedatolisib into Phase 3 fit a portfolio rationalization logic. The asset was pre-Phase 3. The class had produced more failures than successes. Pfizer's oncology pipeline had higher-priority programs competing for the same development resources. From a portfolio management perspective, a $10 million upfront payment plus potential milestone income was a reasonable outcome for a shelved asset.

The question this article examines is whether that outcome was consistent with the asset's risk-adjusted value at the time. The short answer: it was not.

The molecule nobody wanted to develop

Gedatolisib is an intravenously administered, ATP-competitive inhibitor that targets all four Class I PI3K isoforms (p110-alpha/beta/gamma/delta) plus both mTOR complexes (mTORC1 and mTORC2) [5]. This pan-PAM blockade distinguishes it from every other approved drug in the pathway. Alpelisib hits PI3K-alpha alone. Inavolisib is selective for PI3K-alpha. Capivasertib inhibits AKT. Everolimus blocks mTORC1 but not mTORC2. Gedatolisib covers the full pathway.

The mechanistic rationale matters for valuation because it translates into a broader patient population. PIK3CA mutations appear in approximately 40% of HR+/HER2- metastatic breast cancers [2]. The remaining 60% are PIK3CA wild-type, representing an estimated 37,000 patients per year in the United States [2]. Until July 2026, no targeted therapy was approved for the wild-type population. Every existing PAM pathway inhibitor (alpelisib, inavolisib, capivasertib) is restricted to biomarker-selected subsets.

Gedatolisib's mechanism meant it could address both populations. That fact was visible in 2021 from Phase 1b data. It was not a surprise revealed by VIKTORIA-1. The molecule's differentiation was knowable at the time Pfizer licensed it. Whether it was priced into the deal is a separate question.

VIKTORIA-1: the data that rewrote the risk profile

The FDA approval was based on the PIK3CA wild-type cohort of the VIKTORIA-1 trial [1]. The results were unambiguous:

PIK3CA wild-type cohort:

Patients on the gedatolisib triplet experienced a 76% reduction in the risk of progression or death compared to fulvestrant alone. The objective response rate was 32% versus 1%. These are not marginal improvements. They are the kind of results that shift a drug from “interesting mechanism” to “standard of care candidate.”

The PIK3CA-mutant cohort, presented at ASCO 2026, was equally consequential because it included a head-to-head comparison with the existing standard of care [6]:

PIK3CA-mutant cohort:

Gedatolisib doubled the median PFS of alpelisib in a randomized head-to-head comparison and nearly doubled the objective response rate (48.9% vs 26.0%) [6]. The safety profile offered a meaningful differentiator on the toxicity that has most limited PI3K inhibitor use: hyperglycemia occurred at all-grade rates of 15.0% (triplet) and 11.5% (doublet) versus 57.9% for alpelisib [6]. Stomatitis was higher with gedatolisib (61% vs 34%), but metabolic toxicity is the primary reason patients discontinue this drug class, and the four-fold reduction in hyperglycemia is clinically significant [6].

For valuation purposes, VIKTORIA-1 did two things. First, it converted a 15% probability of success into a 65% probability, the historical rate of approval following a positive Phase 3 oncology readout. Second, it established a clinical profile strong enough to support peak sales assumptions at the upper end of analyst estimates. Both inputs feed directly into the rNPV calculation.

The competitive field

The PAM pathway in HR+/HER2- breast cancer now has four approved targeted therapies, each with a different commercial trajectory:

Two patterns emerge from this table. First, the PI3K-alpha-selective inhibitors (alpelisib, inavolisib) are confined to the PIK3CA-mutant population, which is roughly 40% of the addressable patients [2]. Second, the only agent showing strong commercial growth is capivasertib, which targets AKT and is biomarker-selected across PIK3CA/AKT1/PTEN alterations. Piqray's sales declined 15% year-over-year to $382 million, which Novartis attributed to competition [8]. Truqap reached $728 million in its second full year, growing 69% [9].

Gedatolisib enters this field with two structural advantages: it is the only agent approved for PIK3CA wild-type patients, and it demonstrated superior efficacy to alpelisib head-to-head in the mutant population. The constraint is route of administration. All four competitors are oral. Gedatolisib is intravenous. Whether the efficacy advantage compensates for the infusion burden will determine commercial uptake.

The addressable market supports the peak sales assumptions. Celcuity estimates a $5 to $6 billion second-line U.S. market across both PIK3CA wild-type and mutant populations [2]. The broader HR+/HER2- breast cancer market in the United States was approximately $10 billion in 2025 [11]. Analyst consensus places gedatolisib's peak sales between $2.1 billion (Evaluate Pharma, by 2032) and $2.5 to $3 billion (Celcuity management) [4]. Our valuation model uses the midpoint: $2.5 billion.

Valuing the asset at every stage

We applied a simplified rNPV model to gedatolisib at four inflection points. The model assumptions:

• Peak sales: $2.5 billion (midpoint of analyst estimates [4])
• Royalty to Pfizer: low-to-mid teens per license terms [3]
• Gross margin: 88%
• Operating costs: 30% of gross profit
• Discount rate: 10%
• Peak duration: 7 years with ramp, followed by gradual erosion
• Model royalty assumption: 12% (midpoint of stated range)

Stage 1: Pfizer holds the asset (2021, pre-Phase 3)

At the time of the license, gedatolisib was pre-Phase 3. Historical probability of approval for an oncology asset at this stage is approximately 15%. With $300 million in estimated remaining development costs and 5 years to launch:

• Probability of success: 15%
• Risked NPV of commercial cash flows: $5.07 billion
• rNPV = 15% of $5.07B minus $300M = $460 million

Pfizer's risk-adjusted value for the asset was approximately $460 million. They received $10 million upfront and the possibility of up to $330 million in milestones plus royalties.

Stage 2: Celcuity acquires (April 2021)

The asset did not change. Same molecule, same stage, same risk profile. Celcuity's rNPV at acquisition was the same $460 million. What changed was who bore the development risk and who captured the upside. Celcuity paid $10 million for an asset worth $460 million in risk-adjusted terms. The $330 million in milestones and tiered royalties represent the deferred cost of that acquisition, payable only if the asset succeeds.

Stage 3: Phase 3 readout (2025)

VIKTORIA-1 hit its primary endpoint in the wild-type cohort. A positive Phase 3 readout in oncology shifts the probability of approval to approximately 65%. With $100 million in remaining costs (NDA preparation, regulatory) and 2 years to launch:

• Probability of success: 65%
• Risked NPV of commercial cash flows: $6.75 billion
• rNPV = 65% of $6.75B minus $100M = $4.28 billion

The rNPV jumped from $460 million to $4.28 billion. That is a 9.3-fold increase, driven almost entirely by the probability shift from 15% to 65%. The clinical data did not just validate the mechanism. It rewrote the risk profile.

Stage 4: FDA approval (July 14, 2026)

At approval, probability of success reaches 100%. Remaining costs are approximately $50 million in launch expenses.

• Probability of success: 100%
• NPV of commercial cash flows: $8.16 billion
• rNPV = $8.16B minus $50M = $8.11 billion

Five years and $10 million of upfront capital separated Celcuity from an $8.1 billion risk-adjusted asset. The return on the upfront payment alone is 811-fold.

The option Pfizer never exercised

The rNPV analysis shows that Pfizer held an asset worth $460 million in risk-adjusted terms and sold it for $10 million. The gap, approximately $450 million, represents the value Pfizer forfeited. But rNPV alone understates the forfeiture because it treats the development decision as binary: either you invest or you do not. Real options analysis captures what rNPV misses: the value of flexibility.

Pfizer held three embedded options when it controlled gedatolisib:

The option to wait. Pfizer could have delayed the Phase 3 decision, monitoring how the PI3K inhibitor class evolved. The class did improve. Capivasertib launched in 2023 and reached $728 million in 2025 [9]. Inavolisib launched in 2024 [10]. The regulatory environment for PAM pathway inhibitors became more favorable, not less. Had Pfizer waited, the option to proceed with Phase 3 would have gained value as the class de-risked.

The option to expand. Gedatolisib is now in active clinical trials for metastatic castration-resistant prostate cancer (in combination with darolutamide, NCT06190899) and endometrial cancer (the RESOLVE trial, NCT03675893) [12]. A first-line breast cancer trial, VIKTORIA-2, began recruiting in July 2025 with an estimated enrollment of 1,180 patients and primary completion in 2029 [13]. Each of these represents an indication expansion option that Pfizer relinquished at the time of the license. In rNPV terms, these options have value that does not appear in a single-indication model.

The compound option structure. Drug development is a sequence of options. Each successful stage (Phase 3, NDA, approval, label expansion) creates the option to proceed to the next. Pfizer held the first option in the sequence: the decision to invest $300 million in Phase 3. By choosing not to exercise it, Pfizer forfeited not just the Phase 3 option but every downstream option that depended on it.

Using a Black-Scholes approximation for the Phase 3 option, with the $300 million development cost as the strike price and the $5.07 billion NPV as the underlying asset, the option value is positive even at a 15% probability of success. The asset was “in the money” as a development option. Pfizer's decision to license rather than exercise was a portfolio allocation choice, not a valuation-driven one. Pfizer had assets it judged more valuable per dollar of R&D spend. That judgment may have been correct for Pfizer's overall portfolio. But it transferred $450 million in risk-adjusted value, plus the expansion optionality, to Celcuity for $10 million.

Twenty-two years on a clock

The timeline illustrates a pattern we see repeatedly in biotech: value creation is unevenly distributed across time. The 17 years at Wyeth and Pfizer produced scientific knowledge, preclinical data, and early clinical signals. They produced no commercial value. The 5 years at Celcuity produced a registrational trial, an NDA, an FDA approval, and approximately $5.1-5.3 billion in market capitalization [14].

The difference was not the science. The molecule was the same. The difference was the strategic decision to invest in clinical development and the operational discipline to execute a registrational trial. This is the core insight of biotech valuation: value is not a property of the molecule. It is a function of the development decisions made around it.

The regulatory path itself was efficient. Celcuity submitted the NDA in November 2025 under the FDA's Real-Time Oncology Review (RTOR) program. The FDA accepted it in January 2026 with Priority Review and a PDUFA date of July 17, 2026 [15]. The drug held Breakthrough Therapy, Fast Track, and Priority Review designations. The FDA approved it on July 14, three days before the goal date [1].

When the market noticed

Celcuity's stock traded as low as $13.37 in its 52-week range before climbing to a high of $151.02 [14]. The company's market capitalization is approximately $5.1-5.3 billion as of July 2026 [14]. Analyst consensus price targets range from $124 to $139.

The market did not price the value at the licensing deal in April 2021. It did not price it at the start of Phase 3. The largest revaluation occurred at the Phase 3 readout and the NDA filing, when the probability shift from 15% to 65% became public information. By the time of FDA approval, much of the value was already reflected in the stock.

This pattern is consistent with what we have observed across biotech assets. The Phase 3 readout is the dominant value inflection point. Approval is largely a confirmation event. Investors who wait for approval to buy are buying after the largest risk-adjusted revaluation has already occurred.

The implication for BD professionals is that deal timing matters as much as deal structure. Celcuity acquired the asset at the pre-Phase 3 stage, when the risk-adjusted value was $460 million and the upfront cost was $10 million. A deal struck after the Phase 3 readout, when the rNPV was $4.28 billion, would have required a fundamentally different payment structure. The $10 million opportunity existed because Pfizer valued the asset at the pre-Phase 3 stage, when pessimism about the PI3K class was at its peak.

What this case teaches

For pharma portfolio managers. Pfizer's decision was informed by class-level pessimism, not asset-level analysis. The failure of a different PI3K/mTOR drug and Lilly's exit from the class were treated as signals about gedatolisib's prospects. But gedatolisib's mechanism, pan-PI3K plus dual mTOR, was differentiated from the beginning. The class-level reasoning that justified the $10 million exit did not apply to this specific molecule. When shelving assets, evaluate the molecule's differentiation within its class, not just the class's recent track record. The cost of getting this wrong is $450 million in risk-adjusted value, plus whatever the expansion indications eventually produce.

For biotech BD teams. Celcuity's acquisition illustrates a repeatable pattern: identify differentiated assets in out-of-favor classes, acquire them with milestone-heavy structures that preserve cash for development, and execute the clinical program. The milestone structure is important. $10 million upfront with $330 million in milestones means the seller shares in the downside (the milestones never trigger if the drug fails) while the buyer preserves capital for the trial. The value creation happened in VIKTORIA-1. Without positive Phase 3 data, the asset would still be worth $460 million in rNPV terms. The deal structure created the opportunity, but clinical execution created the value.

For investors. The 811-fold return on the upfront payment is not a typical biotech return. It is the return of a company that acquired a differentiated asset at a distressed price and executed clinically. The more relevant investor question is timing. The largest revaluation occurred at the Phase 3 readout, not at approval. By the time the FDA acted, the market had already incorporated most of the probability shift. For investors evaluating similar assets, the lesson is to identify the Phase 3 readout as the critical decision point and to position before it, not after.

Limitations

The rNPV model is simplified for illustrative purposes. A production model would incorporate indication-specific peak sales, geographic pricing assumptions, competitive erosion timing, and detailed cost structures. The $2.5 billion peak sales midpoint is a forward-looking analyst estimate, not realized revenue. Actual peak sales will depend on commercial execution, the pending supplemental NDA for the PIK3CA-mutant indication (expected Q3 2026), and competitive dynamics as Itovebi and Truqap expand their footprints.

The 15% probability of success for pre-Phase 3 oncology is a historical average. Gedatolisib's specific risk profile, including its differentiated mechanism and encouraging Phase 1b data, may have warranted a higher probability. The real options analysis is qualitative. A full real options valuation would model the compound option structure across development stages with calibrated volatility parameters.

The exact year of gedatolisib's discovery at Wyeth could not be independently verified from available sources. Only the general Wyeth origin and Pfizer's continuation after the 2009 acquisition are confirmed [3]. The 22-year timeline referenced in Figure 3 is based on a commonly cited approximate discovery date and should be treated as an estimate.

Conclusion

Gedatolisib's path from a $10 million licensing deal to an $8.1 billion risk-adjusted asset is not a story about a lucky bet. It is a story about how risk-adjusted valuation works in practice and what happens when a large organization values an asset using class-level signals rather than molecule-level analysis.

The frameworks we use on this blog (rNPV, real options, competitive landscape mapping) are not theoretical constructs. Applied to this case, they identify the $460 million in risk-adjusted value that Pfizer held and the $450 million it forfeited. They show that the largest value inflection occurs at the Phase 3 readout, when probability shifts from 15% to 65%. And they demonstrate that deal structure, not just deal price, determines who captures the value created by clinical development.

The difference between a $10 million asset and an $8 billion asset is not the science. The molecule did not change. The difference is the decision to invest in clinical development and the discipline to execute it. For anyone making portfolio decisions in biotech, that is the lesson worth internalizing.

Sources

1. [1] FDA. “FDA approves gedatolisib with fulvestrant with or without palbociclib for HR-positive, HER2-negative locally advanced or metastatic breast cancer.” July 14, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally
2. [2] Roche/Genentech. “FDA approves new targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.” October 2024. https://www.gene.com/media/news-features/fda-approves-new-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation
3. [3] Celcuity Inc. SEC Exhibit 99.3, Gedatolisib License Agreement with Pfizer. April 2021. https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex993.htm
4. [4] Fierce Biotech. “Celcuity's gedatolisib beats Novartis' Piqray in phase 3 breast cancer study.” May 4, 2026. https://www.fiercebiotech.com/biotech/celcuitys-gedatolisib-beats-novartis-piqray-phase-3-breast-cancer-study
5. [5] Drug Hunter. Gedatolisib molecule profile. https://www.drughunter.com/molecule/gedatolisib
6. [6] AJMC. “In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer.” June 19, 2026. https://www.ajmc.com/view/in-viktoria-1-gedatolisib-combos-cut-risk-of-progression-by-half-vs-alpelisib-in-pik3ca-mutant-advanced-breast-cancer
7. [7] CancerNetwork / FDA. “FDA approves everolimus (Afinitor) for metastatic breast cancer.” July 2012. https://www.cancernetwork.com/view/fda-approves-everolimus-afinitor-metastatic-breast-cancer
8. [8] Drugs.com / Novartis Annual Report 2025. Alpelisib (Piqray) approval history and 2025 revenue. https://www.drugs.com/history/piqray.html
9. [9] FDA / AstraZeneca Annual Report 2025. Capivasertib (Truqap) approval and 2025 revenue. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer
10. [10] FDA. “FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.” October 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive
11. [11] Synapse Patsnap / DelveInsight. HR+/HER2- breast cancer market analysis. https://synapse.patsnap.com/article/what-are-the-key-players-in-the-hormone-receptor-positive-her2-negative-breast-cancer-treatment-market
12. [12] National Cancer Institute. Clinical trials using gedatolisib. https://www.cancer.gov/research/participate/clinical-trials/intervention/gedatolisib?pn=1
13. [13] ClinicalTrials.gov. VIKTORIA-2 (NCT06757634). https://clinicaltrials.gov/study/NCT06757634
14. [14] StockTitan / MacroTrends. Celcuity (CELC) market capitalization and stock performance. https://www.stocktitan.net/overview/CELC
15. [15] TechTimes. “FDA rule by July 17: Gedatolisib, first targeted therapy for PIK3CA wild-type breast cancer.” July 10, 2026. https://www.techtimes.com/articles/320113/20260710/fda-rule-july-17-gedatolisib-first-targeted-therapy-pik3ca-wild-type-breast-cancer.htm